請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70406完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳俊任(Chun-Jen Chen) | |
| dc.contributor.author | Hsien-Chan Chiu | en |
| dc.contributor.author | 邱顯展 | zh_TW |
| dc.date.accessioned | 2021-06-17T04:27:29Z | - |
| dc.date.available | 2018-08-16 | |
| dc.date.copyright | 2018-08-16 | |
| dc.date.issued | 2018 | |
| dc.date.submitted | 2018-08-14 | |
| dc.identifier.citation | 1. Joob, B. and V. Wiwanitkit, Linzhi (Ganoderma lucidum); evidence of its clinical usefulness in renal diseases. Journal of Nephropharmacology, 2016. 5(1): p. 9-10.
2. Zhao, L., et al., Extraction, purification, characterization and antitumor activity of polysaccharides from Ganoderma lucidum. Carbohydrate Polymers, 2010. 80(3): p. 783-789. 3. Wang, C.-L., et al., Polysaccharides purified from the submerged culture of Ganoderma formosanum stimulate macrophage activation and protect mice against Listeria monocytogenes infection. Biotechnology Letters, 2011. 33(11): p. 2271. 4. Miyazaki, T. and M. Nishijima, Studies on Fungal Polysaccharides. XXVII. Structural Examination of a Water-soluble, Antitumor Polysaccharide of Ganoderma lucidum. CHEMICAL & PHARMACEUTICAL BULLETIN, 1981. 29(12): p. 3611-3616. 5. Bhagwan, S.S., et al., Ganoderma lucidum: A Potent Pharmacological Macrofungus. Current Pharmaceutical Biotechnology, 2009. 10(8): p. 717-742. 6. Lee, J.M., et al., Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytotherapy Research, 2001. 15(3): p. 245-249. 7. Stanley, G., et al., Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-β1 from prostate cancer cells. Biochemical and Biophysical Research Communications, 2005. 330(1): p. 46-52. 8. Wang, S.Y., et al., The anti‐tumor effect of Ganoderma Lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. International Journal of Cancer, 1998. 70(6): p. 699-705. 9. Paterson, R.R.M., Ganoderma – A therapeutic fungal biofactory. Phytochemistry, 2006. 67(18): p. 1985-2001. 10. Zhao, H., et al., Enteric Mucosal Immune Response might Trigger the Immunomodulation Activity of Ganoderma lucidum Polysaccharide in Mice. Planta Med, 2010. 76(03): p. 223-227. 11. Huie, C.W. and X. Di, Chromatographic and electrophoretic methods for Lingzhi pharmacologically active components. Journal of Chromatography B, 2004. 812(1): p. 241-257. 12. Avci, F.Y. and D.L. Kasper, How Bacterial Carbohydrates Influence the Adaptive Immune System. Annual Review of Immunology, 2010. 28(1): p. 107-130. 13. Wang, G., et al., Enhancement of IL-2 and IFN-γ expression and NK cells activity involved in the anti-tumor effect of ganoderic acid Me in vivo. International Immunopharmacology, 2007. 7(6): p. 864-870. 14. Pang, X., et al., Potential of a Novel Polysaccharide Preparation (GLPP) from Anhui‐Grown Ganoderma lucidum in Tumor Treatment and Immunostimulation. Journal of Food Science, 2007. 72(6): p. S435-S442. 15. Lin, K.-I., et al., Reishi Polysaccharides Induce Immunoglobulin Production through the TLR4/TLR2-mediated Induction of Transcription Factor Blimp-1. Journal of Biological Chemistry, 2006. 281(34): p. 24111-24123. 16. Zhu, X.-L., A.-F. Chen, and Z.-B. Lin, Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. Journal of Ethnopharmacology, 2007. 111(2): p. 219-226. 17. Wang, C.-L., et al., Activation of antitumor immune responses by Ganoderma formosanum polysaccharides in tumor-bearing mice. Applied Microbiology and Biotechnology, 2014. 98(22): p. 9389-9398. 18. de la Cruz-Merino, L., et al., New Insights into the Role of the Immune Microenvironment in Breast Carcinoma. Clinical and Developmental Immunology, 2013. 2013: p. 785317. 19. Martinez, F.O. and S. Gordon, The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Reports, 2014. 6: p. 13. 20. Tötemeyer, S., et al., IFN-γ Enhances Production of Nitric Oxide from Macrophages via a Mechanism That Depends on Nucleotide Oligomerization Domain-2. The Journal of Immunology, 2006. 176(8): p. 4804. 21. Wang, N., H. Liang, and K. Zen, Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance. Frontiers in Immunology, 2014. 5: p. 614. 22. Kerkar, S.P. and N.P. Restifo, Cellular Constituents of Immune Escape within the Tumor Microenvironment. Cancer Research, 2012. 72(13): p. 3125. 23. Wang, M., et al., Role of tumor microenvironment in tumorigenesis. Journal of Cancer, 2017. 8(5): p. 761-773. 24. Zamarron, B.F. and W. Chen, Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression. International Journal of Biological Sciences, 2011. 7(5): p. 651-658. 25. Erez, N., et al., Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner. Cancer Cell, 2010. 17(2): p. 135-147. 26. Cirri, P. and P. Chiarugi, Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer and Metastasis Reviews, 2012. 31(1): p. 195-208. 27. Sica, A. and V. Bronte, Altered macrophage differentiation and immune dysfunction in tumor development. Journal of Clinical Investigation, 2007. 117(5): p. 1155-1166. 28. Krishnan, V., et al., Tumor associated macrophages in gynecologic cancers. Gynecologic Oncology, 2018. 149(1): p. 205-213. 29. Adeegbe, D.O. and H. Nishikawa, Natural and Induced T Regulatory Cells in Cancer. Frontiers in Immunology, 2013. 4: p. 190. 30. Pollard, J.W., Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer, 2004. 4: p. 71. 31. Yeo, E.-J., et al., Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. Cancer research, 2014. 74(11): p. 2962-2973. 32. Gabrilovich, D.I. and S. Nagaraj, Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology, 2009. 9: p. 162. 33. Höchst, B., et al., Differential Induction of Ly6G and Ly6C Positive Myeloid Derived Suppressor Cells in Chronic Kidney and Liver Inflammation and Fibrosis. PLOS ONE, 2015. 10(3): p. e0119662. 34. Youn, J.-I., et al., Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice. The Journal of Immunology, 2008. 181(8): p. 5791. 35. Kumar, V., et al., The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends in immunology, 2016. 37(3): p. 208-220. 36. Bronte, V., et al., Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. The Journal of Experimental Medicine, 2005. 201(8): p. 1257-1268. 37. Talmadge, J.E. and D.I. Gabrilovich, History of myeloid-derived suppressor cells. Nature Reviews Cancer, 2013. 13: p. 739. 38. Ugel, S., et al., Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. The Journal of Clinical Investigation, 2015. 125(9): p. 3365-3376. 39. Benoist, C. and D. Mathis, Treg Cells, Life History, and Diversity. Cold Spring Harbor Perspectives in Biology, 2012. 4(9). 40. Hori, S., T. Nomura, and S. Sakaguchi, Control of Regulatory T Cell Development by the Transcription Factor <em>Foxp3</em>. Science, 2003. 299(5609): p. 1057. 41. Grant, C.R., et al., Regulatory T-cells in autoimmune diseases: Challenges, controversies and—yet—unanswered questions. Autoimmunity Reviews, 2015. 14(2): p. 105-116. 42. Schubert, D., et al., Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nature medicine, 2014. 20(12): p. 1410-1416. 43. Sojka, D.K., A. Hughson, and D.J. Fowell, CTLA-4 is Required by CD4(+)CD25(+) Treg to Control CD4(+) T Cell Lymphopenia-Induced Proliferation. European journal of immunology, 2009. 39(6): p. 1544-1551. 44. Grivennikov, S.I., F.R. Greten, and M. Karin, Immunity, Inflammation, and Cancer. Cell, 2010. 140(6): p. 883-899. 45. Disis, M.L., Immune Regulation of Cancer. Journal of Clinical Oncology, 2010. 28(29): p. 4531-4538. 46. Parameswaran, N. and S. Patial, Tumor Necrosis Factor-α Signaling in Macrophages. Critical reviews in eukaryotic gene expression, 2010. 20(2): p. 87-103. 47. Pfeffer, K., Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine & Growth Factor Reviews, 2003. 14(3): p. 185-191. 48. Arango Duque, G. and A. Descoteaux, Macrophage Cytokines: Involvement in Immunity and Infectious Diseases. Frontiers in Immunology, 2014. 5: p. 491. 49. Erta, M., A. Quintana, and J. Hidalgo, Interleukin-6, a Major Cytokine in the Central Nervous System. International Journal of Biological Sciences, 2012. 8(9): p. 1254-1266. 50. Luckett-Chastain, L., et al., IL-6 influences the balance between M1 and M2 macrophages in a mouse model of irritant contact dermatitis. The Journal of Immunology, 2016. 196(1 Supplement): p. 196.17. 51. Rincon, M., Special issue on Interleukin-6 (IL-6). International Journal of Biological Sciences, 2012. 8(9): p. 1225-1226. 52. Croxford, A.L., P. Kulig, and B. Becher, IL-12-and IL-23 in health and disease. Cytokine & Growth Factor Reviews, 2014. 25(4): p. 415-421. 53. Watford, W.T., et al., The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine & Growth Factor Reviews, 2003. 14(5): p. 361-368. 54. Ben-Sasson, S.Z., et al., IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2009. 106(17): p. 7119-7124. 55. Guo, C.-J., et al., Interleukin-1β stimulates macrophage inflammatory protein-1α and -1β expression in human neuronal cells (NT2-N). Journal of neurochemistry, 2003. 84(5): p. 997-1005. 56. Bogdan, C., Nitric oxide and the immune response. Nature Immunology, 2001. 2: p. 907. 57. Bogdan, C., M. Röllinghoff, and A. Diefenbach, The role of nitric oxide in innate immunity. Immunological Reviews, 2002. 173(1): p. 17-26. 58. Mills, C.D., et al., M-1/M-2 Macrophages and the Th1/Th2 Paradigm. The Journal of Immunology, 2000. 164(12): p. 6166. 59. Mosser, D.M. and X. Zhang, Interleukin-10: new perspectives on an old cytokine. Immunological reviews, 2008. 226: p. 205-218. 60. Chadban, S.J., et al., Interleukin-10 differentially modulates MHC class II expression by mesangial cells and macrophages in vitro and in vivo. Immunology, 1998. 94(1): p. 72-78. 61. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. The Journal of Experimental Medicine, 1992. 175(3): p. 671-682. 62. Travis, M.A. and D. Sheppard, TGF-β Activation and Function in Immunity. Annual review of immunology, 2014. 32: p. 51-82. 63. Massagué, J., TGFβ in Cancer. Cell, 2008. 134(2): p. 215-230. 64. Allavena, P., et al., The Yin‐Yang of tumor‐associated macrophages in neoplastic progression and immune surveillance. Immunological Reviews, 2008. 222(1): p. 155-161. 65. Munder, M., Arginase: an emerging key player in the mammalian immune system. British Journal of Pharmacology, 2009. 158(3): p. 638-651. 66. Dzik, J.M., Evolutionary Roots of Arginase Expression and Regulation. Frontiers in Immunology, 2014. 5: p. 544. 67. Stempin, C.C., et al., Arginase in Parasitic Infections: Macrophage Activation, Immunosuppression, and Intracellular Signals. Journal of Biomedicine and Biotechnology, 2010. 2010: p. 683485. 68. Nio, J., et al., Cellular expression of murine Ym1 and Ym2, chitinase family proteins, as revealed by in situ hybridization and immunohistochemistry. Histochemistry and Cell Biology, 2004. 121(6): p. 473-482. 69. Raes, G., et al., Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. Journal of Leukocyte Biology, 2002. 71(4): p. 597-602. 70. Spittau, B., et al., Endogenous transforming growth factor‐beta promotes quiescence of primary microglia in vitro. Glia, 2012. 61(2): p. 287-300. 71. Raes, G., et al., Arginase-1 and Ym1 Are Markers for Murine, but Not Human, Alternatively Activated Myeloid Cells. The Journal of Immunology, 2005. 174(11): p. 6561. 72. Qian, B.-Z., et al., CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis. Nature, 2011. 475(7355): p. 222-225. 73. Germano, G., et al., Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. Cancer Cell, 2013. 23(2): p. 249-262. 74. Genard, G., S. Lucas, and C. Michiels, Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. Frontiers in Immunology, 2017. 8: p. 828. 75. Xu, M., et al., Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype. The Journal of Immunology, 2015. 194(10): p. 4997. 76. Schmid, M.C. and J.A. Varner, Myeloid Cells in the Tumor Microenvironment: Modulation of Tumor Angiogenesis and Tumor Inflammation. Journal of Oncology, 2010. 2010: p. 201026. 77. Sica, A. and A. Mantovani, Macrophage plasticity and polarization: in vivo veritas. The Journal of Clinical Investigation, 2012. 122(3): p. 787-795. 78. Zhou, Y., et al., Different distributions of M1 and M2 macrophages in a mouse model of laser-induced choroidal neovascularization. Molecular Medicine Reports, 2017. 15(6): p. 3949-3956. 79. Expression of the macrophage-specific antigen F4/80 during differentiation of mouse bone marrow cells in culture. The Journal of Experimental Medicine, 1981. 154(3): p. 713-725. 80. Papatriantafyllou, M., Intracellular MHC class II: not just hiding. Nature Reviews Immunology, 2011. 11: p. 304. 81. Gorelik, L. and R.A. Flavell, Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Medicine, 2001. 7: p. 1118. 82. Grujic, M., et al., The Role of CD80/CD86 in Generation and Maintenance of Functional Virus-Specific CD8<sup>+</sup> T Cells in Mice Infected with Lymphocytic Choriomeningitis Virus. The Journal of Immunology, 2010. 185(3): p. 1730. 83. Lanier, L.L., et al., CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. The Journal of Immunology, 1995. 154(1): p. 97. 84. Kuang, D.-M., et al., Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. The Journal of Experimental Medicine, 2009. 206(6): p. 1327-1337. 85. Liu, M., et al., Dectin-1 Activation by a Natural Product β-Glucan Converts Immunosuppressive Macrophages into an M1-like Phenotype. Journal of immunology (Baltimore, Md. : 1950), 2015. 195(10): p. 5055-5065. 86. Wargo, J.A., et al., Monitoring immune responses in the tumor microenvironment. Current opinion in immunology, 2016. 41: p. 23-31. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70406 | - |
| dc.description.abstract | 台灣紫芝 (Ganoderma formosanum)為台灣特有靈芝品種，本實驗室以液態醱酵培養台灣紫芝菌絲體，並以膠體過濾純化出台灣紫芝胞外多醣體PS-F2。先前的研究指出將PS-F2以腹腔注射或口服方式給予帶有腫瘤之小鼠，具有抗腫瘤功用；此外先前研究結果顯示PS-F2可以透過TLR-4, CR3, Dectin-1等受器活化下游的訊息傳導，導致巨噬細胞被活化。目前已知巨噬細胞可分化為促發炎反應的M1巨噬細胞及抑制發炎反應的M2巨噬細胞，而在腫瘤微環境中，tumor-associated macrophage (TAM)通常受腫瘤細胞影響而分化為M2-like巨噬細胞，進而抑制抗腫瘤之免疫反應。基於先前之研究成果，本研究想進一步探討PS-F2是否可將TAM轉變成M1型態巨噬細胞，而達到抑制腫瘤的效果。結果顯示PS-F2可刺激M2巨噬細胞分泌發炎細胞激素TNF-α及IL-6，並提升細胞表面CD86及CD40之表現。此外，PS-F2之刺激也可誘發M1巨噬細胞標誌基因iNOS、IL-12、IL-6、IL-1β、IFN-β及TNF-α之表現，並抑制M2巨噬細胞標誌基因arginase 1、TGF-β之表現。從C26腫瘤分離出之TAM以PS-F2刺激後，在基因表現和細胞激素的分泌亦可得到相似之結果。此外我們發現M2巨噬細胞抑制T細胞增生的能力在給予PS-F2後有減緩的情形，這些結果顯示PS-F2之刺激可促使TAM由M2-like轉變成為M1型巨噬細胞，進而達到抑制腫瘤生長之效果。 | zh_TW |
| dc.description.abstract | Ganoderma formosanum is a unique species of Ganoderma isolated in Taiwan. Our previous studies showed that PS-F2, an extracellular polysaccharide fraction purified from the submerged culture of G. formosanum, could active macrophages by Toll-like receptor (TLR)-4, complement receptor (CR) 3 and Dectin-1, and serve as a Th1 adjuvant in vivo. PS-F2 also exhibits antitumor activity when given intraperitoneally or orally to mice. In this study, we investigated whether PS-F2 exerts the antitumor activity via modulating the polarization of M2-like tumor-associated macrophages (TAMs). Our data showed that in both M0 and IL-4-polarized M2 bone marrow derived macrophages (BMDMs), PS-F2 stimulated the production of proinflammatory cytokines TNF-α and IL-6, and the surface expression of CD86, CD40. In addition, PS-F2 stimulated the expression of M1 macrophage signature genes iNOS, IL-12, IL-6, IL-1β, IFN-β and TNF-α, while downregulating the expression of M2 macrophage-related genes arginase1, TGF-β, and Ym-1. Similar results were obtained when primary TAMs isolated from C26 tumor-bearing mice were treated with PS-F2. Furthermore, when M2 macrophages were treated with PS-F2, their suppressive effect on T cell proliferation was alleviated. Taken together, our data demonstrate that PS-F2 stimulation can repolarize protumor M2-like TAMs into antitumor M1 macrophages, resulting in the suppression of tumor growth. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T04:27:29Z (GMT). No. of bitstreams: 1 ntu-107-R05b22009-1.pdf: 3789682 bytes, checksum: e3ef275e84375578c7fee241063c1a09 (MD5) Previous issue date: 2018 | en |
| dc.description.tableofcontents | 中文摘要............................................................................................................................I
Abstract ............................................................................................................................II 目錄.................................................................................................................................III 圖表目錄.........................................................................................................................VI 縮寫表............................................................................................................................VII 一、緒論...........................................................................................................................1 1. 靈芝簡介................................................................................................................1 2. 靈芝多醣體............................................................................................................2 3. 巨噬細胞................................................................................................................3 4. 腫瘤微環境............................................................................................................4 4.1 腫瘤相關纖維母細胞........................................................................................4 4.2 腫瘤相關巨噬細胞............................................................................................4 4.3 骨髓衍生型抑制細胞........................................................................................5 4.4 調節性 T 細胞....................................................................................................6 5. 發炎反應和腫瘤生成............................................................................................6 5.1 促發炎反應........................................................................................................6 5.2 抑制發炎反應....................................................................................................8 二、研究動機...................................................................................................................9 三、材料與方法.............................................................................................................10 1. 從 Ganoderma formosanum 純化 PS-F2.............................................................10 1.1 培養基配置及使用的試劑..............................................................................10 1.2 Ganoderma formosanum 的發酵......................................................................10 1.3 純化目標多醣 PS-F2.......................................................................................11 1.4 測定多醣濃度..................................................................................................11 IV 2. 分析 BMDMs 給予 PS-F2 後的免疫反應..........................................................12 2.1 使用細胞株以及相關試劑..............................................................................12 2.2 骨髓衍生化巨噬細胞 (BMDMs)的製備.......................................................12 2.3 用 Flow Cytometry 來分析 BMDMs 上的表面標誌......................................13 2.4 抽 BMDMs 的 RNA 並轉為 cDNA.................................................................14 2.5 用 Real-time Quantitative PCR 來分析 BMDMs 的基因表現.......................15 2.6 分析 BMDMs 的 cytokine 分泌量..................................................................16 2.7 巨噬細胞免疫抑制活性測試..........................................................................17 3. 分析 TAMs 給予 PS-F2 後的免疫反應..............................................................18 3.1 使用細胞株以及相關試劑..............................................................................18 3.2 腫瘤相關巨噬細胞 (TAMs)的製備...............................................................18 3.3 抽 TAMs 的 RNA 並轉為 cDNA....................................................................19 3.4 用 Real-time Quantitative PCR 來分析 TAMs 的基因表現............................20 3.5 分析 TAMs 的 cytokine 分泌量.......................................................................20 4. 統計與繪圖軟體之分析......................................................................................21 四、實驗結果.................................................................................................................22 1. PS-F2 對 M0 macrophages 的影響.......................................................................22 1.1 M0 巨噬細胞的分化效果和 PS-F2 對其表面型態的改變.............................22 1.2 PS-F2 使得 M0 巨噬細胞表現出 M1 巨噬細胞的特徵.................................22 2. PS-F2 對 M2 巨噬細胞的影響.............................................................................24 2.1 PS-F2 對 M2 巨噬細胞型態的改變.................................................................24 2.2 PS-F2 使得 M2 巨噬細胞表現出 M1 巨噬細胞的特徵.................................24 2.3 M2 巨噬細胞的免疫抑制作用在 PS-F2 刺激後有減緩的情形.....................25 3. PS-F2 對 TAMs 的影響........................................................................................26 3.1 TAMs 的純化....................................................................................................26 V 3.2 PS-F2 使得 TAMs 表現出 M1 巨噬細胞的特徵.............................................26 五、討論……….............................................................................................................28 六、圖表.........................................................................................................................31 七、參考文獻.................................................................................................................49 | |
| dc.language.iso | zh-TW | |
| dc.subject | 台灣紫芝 | zh_TW |
| dc.subject | 多醣體 | zh_TW |
| dc.subject | 骨髓衍生巨噬細胞 | zh_TW |
| dc.subject | T 細胞增生 | zh_TW |
| dc.subject | 腫瘤相關巨噬細胞 | zh_TW |
| dc.subject | T cell proliferation | en |
| dc.subject | Ganoderma formosanum | en |
| dc.subject | tumor associated macrophages (TAMs) | en |
| dc.subject | extracellular polysaccharide | en |
| dc.subject | bone marrow derived macrophages (BMDMs) | en |
| dc.title | 探討台灣紫芝多醣體對免疫抑制性巨噬細胞的影響 | zh_TW |
| dc.title | Effects of Ganoderma formosanum polysaccharides on
immunosuppressive macrophages | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 106-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 江浩森(Hai-Sen Chiang),陳念榮(Nien-Jung Chen) | |
| dc.subject.keyword | 台灣紫芝,多醣體,骨髓衍生巨噬細胞,T 細胞增生,腫瘤相關巨噬細胞, | zh_TW |
| dc.subject.keyword | Ganoderma formosanum,extracellular polysaccharide,bone marrow derived macrophages (BMDMs),T cell proliferation,tumor associated macrophages (TAMs), | en |
| dc.relation.page | 54 | |
| dc.identifier.doi | 10.6342/NTU201802984 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2018-08-14 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科技學系 | zh_TW |
| 顯示於系所單位： | 生化科技學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-107-1.pdf 未授權公開取用 | 3.7 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。